TY - JOUR
T1 - Implications of treating hepatitis C Virus infection among patients awaiting cadaveric liver transplant
T2 - A single-center experience
AU - Ofosu, Andrew
AU - Durand, Christine M.
AU - Saberi, Behnam
AU - Alqahtani, Saleh
AU - Ucbilek, Enver
AU - Belden, Maura
AU - Cameron, Andrew M.
AU - Gurakar, Ahmet
N1 - Publisher Copyright:
© Başkent University 2015 Printed in Turkey. All Rights Reserved.
PY - 2015/11
Y1 - 2015/11
N2 - Objectives: We examined hepatitis C virus positivity among the donors in our center to investigate whether hepatitis C treatment affected liver trans - plant Model for End-Stage Liver Disease. Materials and Methods: We retrospectively reviewed all deceased-donor liver transplants performed between January 2013 and December 2014 at our center, with the primary indication of hepatitis C virus. Baseline demographic and laboratory characteristics of recipients and donors were collected. Statistical analyses were done with P values ≤.05 considered significant. Results: Seventy-five liver transplants were performed, and 62 of them were hepatitis C virus RNApositive at the time of liver transplant donor offer. In 2013, during the Pre-Direct Antiviral Agents era, 14 of 33 hepatitis C virus RNA-positive recipients (42%) were matched to hepatitis C virus-positive donors. During the Direct Antiviral Agents era in 2014, this ratio was 38% (11/29) (P =.72). The mean Model for End-Stage Liver Disease at transplant of the 62 hepatitis C virus RNA-positive recipients was 29, whereas the mean Model for End-Stage Liver Disease of 13 hepatitis C virus RNA-negative recipients was 31. This was not statistically significant (P =.25). Conclusions: Although hepatitis C virus treatment before liver transplant is an attractive option to eliminate the risk of complications because of recurrent hepatitis C virus after liver transplant, its potential effect on limiting the donor pool for the recipient must also be considered. In our observation, 40% of our donor pool consists of hepatitis C viruspositive donors. Further multiregional studies are warranted to verify this observation and to see the potential effect of direct antiviral agent treatment into waiting times and the Model for End-Stage Liver Disease at organ allocation.
AB - Objectives: We examined hepatitis C virus positivity among the donors in our center to investigate whether hepatitis C treatment affected liver trans - plant Model for End-Stage Liver Disease. Materials and Methods: We retrospectively reviewed all deceased-donor liver transplants performed between January 2013 and December 2014 at our center, with the primary indication of hepatitis C virus. Baseline demographic and laboratory characteristics of recipients and donors were collected. Statistical analyses were done with P values ≤.05 considered significant. Results: Seventy-five liver transplants were performed, and 62 of them were hepatitis C virus RNApositive at the time of liver transplant donor offer. In 2013, during the Pre-Direct Antiviral Agents era, 14 of 33 hepatitis C virus RNA-positive recipients (42%) were matched to hepatitis C virus-positive donors. During the Direct Antiviral Agents era in 2014, this ratio was 38% (11/29) (P =.72). The mean Model for End-Stage Liver Disease at transplant of the 62 hepatitis C virus RNA-positive recipients was 29, whereas the mean Model for End-Stage Liver Disease of 13 hepatitis C virus RNA-negative recipients was 31. This was not statistically significant (P =.25). Conclusions: Although hepatitis C virus treatment before liver transplant is an attractive option to eliminate the risk of complications because of recurrent hepatitis C virus after liver transplant, its potential effect on limiting the donor pool for the recipient must also be considered. In our observation, 40% of our donor pool consists of hepatitis C viruspositive donors. Further multiregional studies are warranted to verify this observation and to see the potential effect of direct antiviral agent treatment into waiting times and the Model for End-Stage Liver Disease at organ allocation.
KW - Direct antivirals agents
KW - Hepatitis C
KW - Liver transplant
KW - MELD score
KW - Waiting list
UR - http://www.scopus.com/inward/record.url?scp=84953857695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953857695&partnerID=8YFLogxK
U2 - 10.6002/ect.tdtd2015.L16
DO - 10.6002/ect.tdtd2015.L16
M3 - Article
C2 - 26640901
AN - SCOPUS:84953857695
SN - 1304-0855
VL - 13
SP - 7
EP - 10
JO - Experimental and Clinical Transplantation
JF - Experimental and Clinical Transplantation
ER -